BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: von Allmen D. Pediatric Crohn's Disease. Clin Colon Rectal Surg 2018;31:80-8. [PMID: 29487490 DOI: 10.1055/s-0037-1609022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Hejazi R, Hasosah M. Tuberculosis, onychomycosis and immune deficiency in complicated Crohn's disease. BMJ Case Rep 2019;12:e228986. [PMID: 31383674 DOI: 10.1136/bcr-2018-228986] [Reference Citation Analysis]
2 Sassine S, Savoie Robichaud M, Lin YF, Djani L, Cambron-Asselin C, Qaddouri M, Zekhnine S, Grzywacz K, Groleau V, Dirks M, Drouin É, Halac U, Marchand V, Girard C, Courbette O, Patey N, Dal Soglio D, Deslandres C, Jantchou P. Changes in the clinical phenotype and behavior of pediatric luminal Crohn's disease at diagnosis in the last decade. Dig Liver Dis 2021:S1590-8658(21)00783-0. [PMID: 34756526 DOI: 10.1016/j.dld.2021.09.012] [Reference Citation Analysis]
3 Sýkora J, Pomahačová R, Kreslová M, Cvalínová D, Štych P, Schwarz J. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol 2018; 24(25): 2741-2763 [PMID: 29991879 DOI: 10.3748/wjg.v24.i25.2741] [Cited by in CrossRef: 153] [Cited by in F6Publishing: 121] [Article Influence: 38.3] [Reference Citation Analysis]
4 Salvador-Martín S, Melgarejo-Ortuño A, López-Fernández LA. Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease. Pharmaceutics 2021;13:1786. [PMID: 34834201 DOI: 10.3390/pharmaceutics13111786] [Reference Citation Analysis]